VIRMA and colorectal carcinoma: Mechanistically, CAF‐derived EV‐packaged circTAX1BP1 is delivered to colorectal cancer (CRC) cells, where it binds to VIRMA and promotes its lactylation at lysine residue 1713 by recruiting AARS2.